Nifedipine Tablet

Product Composition & Structural Formats

We supply Nifedipine in exact, internationally standardized strengths, optimized for immediate-release emergency titration or controlled-release daily maintenance.

Active Ingredient	Available Strengths	Formulation Mechanism	Primary Clinical Target
Nifedipine IP / BP / USP	10 mg	Immediate or Modified Release	Acute Titration / Tocolysis: For rapid blood pressure adjustment or suppression of premature labor.
Nifedipine IP / BP / USP	20 mg	Sustained / Retard Matrix	Daily Maintenance: Continuous 12-to-24-hour plasma concentration for chronic hypertension and angina.

Nifedipine Tablet

Nifedipine Tablets (10 mg / 20 mg)

Healthy Life Pharma Private Limited, along with our specialized global export and marketing division Healthy Inc, is a leading Indian manufacturer, CDMO services provider, and wholesale exporter of advanced cardiovascular, internal medicine, and maternal-fetal therapeutics. We manufacture ultra-high-purity, kinetically stable Nifedipine Tablets within our WHO–GMP certified, high-precision solid dosage manufacturing installations. This foundational "Dihydropyridine Calcium Channel Blocker" serves as a massive-volume strategic export to cardiology networks, public hospital infrastructures, national health ministry tenders, and international B2B pharmaceutical marketplaces across Africa, the CIS region, LATAM, and Southeast Asia.

Product Overview

This formulation operates as a "Vascular Smooth Muscle Relaxant." It ensures patient safety and cardiovascular stabilization by selectively blocking calcium influx channels, physically reducing peripheral arterial resistance and lowering systemic blood pressure.

• Mechanism 1 (L-Type Calcium Channel Antagonism): Nifedipine physically binds to and chemically blocks L-type voltage-gated calcium channels within vascular smooth muscle cells and myocardial tissue.

• Mechanism 2 (Arterial Vasodilation): By halting calcium influx, it chemically inhibits the calcium-calmodulin binding complex necessary to activate myosin light-chain kinase. This physically prevents muscle contraction, inducing profound systemic arterial vasodilation.

• Mechanism 3 (Myocardial Workload Reduction): Broad vasodilation physically drops total peripheral resistance (afterload). This chemically reduces cardiac workload and oxygen consumption, physically expanding coronary blood flow to reverse myocardial ischemia (angina).

Product Composition & Structural Formats

We supply Nifedipine in exact, internationally standardized strengths, optimized for immediate-release emergency titration or controlled-release daily maintenance.

Active Ingredient	Available Strengths	Formulation Mechanism	Primary Clinical Target
Nifedipine IP / BP / USP	10 mg	Immediate or Modified Release	Acute Titration / Tocolysis: For rapid blood pressure adjustment or suppression of premature labor.
Nifedipine IP / BP / USP	20 mg	Sustained / Retard Matrix	Daily Maintenance: Continuous 12-to-24-hour plasma concentration for chronic hypertension and angina.

Technical & Logistics Specifications

• HS Code: 3004.90.99 (Medicaments acting on the cardiovascular system / Calcium channel blockers)

• CAS Number: 21829-25-4 (Nifedipine)

• Dosage Form: Oral Solid Tablet (Film-Coated, Modified-Release Matrix)

• Packaging Configurations: 10 or 14 Tablets per Blister packed exclusively in premium, high-barrier Alu-Alu (Cold-Form Foil) or deep-amber PVC/PVDC strips. Nifedipine is highly physically sensitive to light; our multi-layer opaque foil configuration completely protects molecular stability, ensuring a full 36-month shelf life in hot, humid Zone IVb tropical environments.

Manufacturing Authority & Compliance

• Advanced Photo-Shielding Engineering: Nifedipine crystals physically undergo rapid chemical degradation when exposed to specific wavelengths of ambient daylight. Our production lines utilize Isolated UV-Filtered Light Enclosures during granulating and tableting, protecting the active chemical core prior to final opaque blister wrapping.

• Sustained-Release Polymer Compression: For our 20mg modified-release variants, we utilize an Advanced Hydrophilic Polymer Matrix (HPMC) Core. This physically controls the entry of gastrointestinal fluids, chemically releasing the drug uniformly over an extended window to eliminate dangerous blood pressure spikes.

• Comparative Dissolution Profiling: Every production batch physically undergoes Automated Dissolution Profiling, chemically validating that our generic solid oral doses match the exact kinetic curves and bioequivalence standards of global innovator references (such as Adalat).

Primary Indications

• Cardiology: Management and long-term prophylaxis of Chronic Stable Angina Pectoris and Vasospastic (Prinzmetal’s) Angina.

• Internal Medicine: Treatment of mild-to-moderate Essential Hypertension.

• Obstetrics & Gynecology: Off-label deployment as a frontline Tocolytic Agent to delay premature labor and manage severe acute hypertension in pregnancy (Pre-Eclampsia).

Usage Instructions

• Administration Vector: Sustained-release or modified tablets must be swallowed physically whole with a glass of water. Do not crush, chew, or break the tablet matrix, as destroying the polymer shield chemically releases the entire dose at once, causing severe, dangerous hypotension.

• The Grapefruit Interaction: Patients must avoid consuming grapefruit juice alongside Nifedipine. Grapefruit chemically inhibits hepatic CYP3A4 enzymes, physically increasing drug plasma levels to toxic thresholds.

• Abrupt Cessation Warning: Advise clinical networks that patients must never halt anti-anginal treatment abruptly. Sudden withdrawal can chemically cause a rebound phenomenon, physically triggering acute coronary spasms or hypertensive crises.

Safety Warning: POTENT CARDIOVASCULAR MODIFIER. For Professional Medical Supervision Only. Reflex Tachycardia Risk: Immediate-release forms may physically trigger abrupt vasodilation followed by sympathetic Reflex Tachycardia; manage acute titration windows under clinical observation. Peripheral Edema Note: Vasodilation may physically cause localized fluid retention in the lower extremities (ankle swelling); evaluate cardiac parameters chemically if fluid shifts persist. Contraindication: Do not use in cases of cardiogenic shock, severe aortic stenosis, within the first 4 weeks of a myocardial infarction, or known hypersensitivity to dihydropyridine derivatives.

Global CDMO Services & Wholesale Supply Chain

Healthy Life Pharma Private Limited and Healthy Inc provide complete, internationally validated Third-Party Contract Manufacturing (CDMO Services) and bulk private-label production for generic Nifedipine Tablets. Whether you are executing a high-volume procurement contract for a National Health Ministry Tender across Sub-Saharan Africa, stocking an institutional hospital cooperative in the CIS, or maintaining an inventory listing on an international digital B2B Pharmaceutical Marketplace across Southeast Asia or LATAM, we deliver all required documentation (WHO-GMP Certificate, Certificates of Pharmaceutical Product - COPP, Certificates of Analysis - COA, Stability Testing Matrix Sheets, and Complete CTD Format Dossier sets) for rapid entry registration.

Commercial & Bulk Procurement Inquiries:

• Corporate Head Office: Mumbai, Maharashtra, India

• Primary Manufacturing Base: Boisar, Maharashtra, India

• WhatsApp / Direct Call: +91 7710003340

• Corporate Email: info@healthyinc.co.in